Trial Profile
Phase II Randomized Trial of Stereotactic Radiotherapy (SRT) Followed by Intravitreal Aflibercept Injection for Patients With Ocular Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Aflibercept (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions
- 04 Jan 2023 Status changed from active, no longer recruiting to completed.
- 21 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 07 Dec 2020 Planned End Date changed from 1 Jul 2021 to 1 Jul 2024.